Shares of Halyard Health Inc (NYSE:HYH) ended Thursday session in green amid volatile trading. The shares closed up +0.10 points or 0.29% at $34.18 with 164,759.00 shares getting traded. Post opening the session at $33.94, the shares hit an intraday low of $33.84 and an intraday high of $34.26 and the price vacillated in this range throughout the day. The company has a market cap of $1.58 billion and the numbers of outstanding shares have been calculated to be 46.67 million shares.
Halyard Health Inc (HYH) announced that it will webcast its conference call discussing financial results and business highlights for the third quarter 2016 on Wednesday, Nov. 2 at 9 a.m. ET. The company will issue a news release detailing third quarter results before the market opens that same day.
The conference call will be hosted by Robert Abernathy, chairman and chief executive officer, and Steve Voskuil, chief financial officer.
To join the live conference call, dial 877.240.5772 in the United States. A simultaneous webcast of the call and a related presentation will be accessible via the Investors section of the Halyard Health website, https://halyardhealth.investorroom.com/.
A replay of the conference call will be available Nov. 2 at noon ET by dialing 877.344.7529 in the United States and entering passcode 10094658. It will be available for one week. A replay of the webcast also will be accessible in the Investors section of the website, approximately one hour following the completion of the conference call.
Shares of Avinger Inc (NASDAQ:AVGR) ended Thursday session in red amid volatile trading. The shares closed down -0.02 points or -0.41% at $4.80 with 159,693.00 shares getting traded. Post opening the session at $4.88, the shares hit an intraday low of $4.77 and an intraday high of $4.95 and the price vacillated in this range throughout the day. The company has a market cap of $103.19 million and the numbers of outstanding shares have been calculated to be 21.41 million shares.
Avinger Inc (AVGR) announced that it has received expanded indications from the U.S. Food and Drug Administration (FDA) recognizing the Pantheris™ Lumivascular atherectomy system as a technology that can be used for both therapeutic and diagnostic purposes.
Pantheris is the first and only image-guided atherectomy device to receive clearance for diagnostic imaging as well as for the simultaneous treatment of PAD. This expanded indication clarifies that, in addition to treatment of PAD, Pantheris may be used by physicians to identify the vessel lumen and wall structures such as intima, internal elastic lamina (IEL), media, external elastic lamina (EEL) and stent struts, as well as vessel morphologies such as calcium, thrombus, fibroatheromas, and necrotic cores.